DNDi has various types of agreements with its partners worldwide, such as Research Services Agreements, Material Transfer Agreements, Research and License Agreements, Collaboration Agreements, Clinical Trial Agreements, Financial Agreements, etc.
Research Services Agreements regulate contractual relationship between research service providers and DNDi. Material Transfer Agreements provide access to compounds for testing. In addition to these agreements, DNDi seeks to conclude Research and License Agreements with key partners which involve a greater commitment from both parties. The core of these agreements concern IP ownership (generally owned by the partner and in some cases co-owned), and licensing clauses. Several conditions are required to ensure availability and affordability of the treatment and respect of DNDi’s IP policy objectives. As a not-for-profit and patient-needs driven organization, DNDi seeks transparency to efficiently address urgent patient needs. Therefore, the licenses should be:
- Royalty-free to ensure the lowest possible price
- Sub-licensable, or in other terms, contain the authorization to disclose the obtained information to another party in order to continue product development
- Worldwide coverage both for R&D and for manufacture
- Non-exclusive to enable third parties to enter the field (included in our most innovative agreements)
An important objective for DNDi’s agreement is limited confidentiality – to make available all information generated on the product during its development in the form of publications or databases.
Pharmaceuticals
AbbVie (USA) – Projects: Screening / Lead optimization / Leish H2L / Chagas H2L / Chagas C205 Series / Flubendazole Macrofilaricide / AbbV4083 / ‘4-in-1’ LPV/r/ABC/3TC
Astellas Pharma (Japan) – Projects: Screening
AstraZeneca (UK) – Projects: Screening / Lead optimization/ Leish H2L / Chagas H2L
Avista Pharma (formerly SCYNEXIS) (USA) – Projects: Acoziborole / SCYX-1330682 SCYX-1608210 / DNDi-5421 DNDi 5610
Bayer Healthcare (Germany) – Projects: Screening / Emodepside
Bristol-Myers Squibb (USA) – Projects: Screening
Cipla Inc. (India) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI / ASMQ
Daiichi Sankyo (Japan) – Projects: Screening / Daiichi Sankyo LH2L / Daiichi Sankyo CH2L
Debiopharm (Switzerland) – Projects: Discovery
Eisai Co., Ltd. (Japan) – Projects: Screening / Leish H2L / Chagas H2L / Azoles E1224 / New benz regimens +/- fosravuconazole / Fosravuconazole
E.I du Pont Nemours (USA) – Projects: Screening
Farmanguinhos (Fiocruz) (Brazil) – Projects: ASMQ
GeneDesign Inc. (Japan) – Projects: CpG-D35
Gilead Sciences (USA) – Projects: Fexinidazole (HAT)
GlaxoSmithKline (Spain) – Projects: Screening / Lead optimization / Leish H2L / New treatments for HIV/VL / Chagas C205 series / Chagas H2L
GNF Novartis, Genomics Institute of the Novartis Research Foundation (USA) – Projects: Screening
Humax Pharmaceutical (Colombia) – Projects: Anfoleish
Johnson & Johnson (USA) – Projects: Screening / Flubendazole Macrofilaricide
Janssen (Belgium) – Projects: Screening
Janssen Research & Development (USA) – Projects: Flubendazole Macrofilaricide
LAFEPE (Brazil) – Projects: Paediatric dosage form of benznidazole
Mercachem (The Netherlands) – Projects: Screening
Merck (USA) – Projects: Screening / Lead optimization / Leish H2L / Chagas H2L
Merck Serono (Germany) – Projects: Screening
Optimed (France) – Projects: Fexinidazole-Miltefosine combination
Paladin Labs (Canada) – Projects: VL-0208
Pharco Pharmaceuticals Inc. (Egypt) – Projects: Ravidasvir/ Sofosbuvir
Pfizer Ltd. (UK) – Projects: Screening / Lead optimization/ Aminopyrazoles
Sanofi (France) – Projects: Screening / Lead optimization/ Leish H2L / Chagas H2L / Chagas C205 series / ASAQ / Fexinidazole (HAT)
Sanofi-Chinoin (Hungary) – Projects: Fexinidazole-Miltefosine combination
Sara Pharm (Romania) – Projects: DNDi-6148
Shionogi & Co. Ldt (Japan) – Projects: Screening / Leish H2L / Chagas H2L
Syngene (India) – Projects: DNDi-6148 / DNDi-0690
Takeda Pharmaceutical Company Ltd. (Japan) – Projects: Screening / Aminopyrazoles / Leish H2L / Chagas H2L / DNDi-5561
Zenufa Laboratories Ltd (Tanzania) – Projects: ASAQ
Biotechs
Anacor Pharmaceuticals (USA) – Projects: Screening / Lead optimization / SCYX-1330682 SCYX-1608210 / Leish H2L / DNDi-5421 DNDi-5610 / Acoziborole / DNDi-6148 / Oxachagas / Chagas C205 series
Celgene Global Health (USA) – Projects: Screening / Lead optimization / CGH VL series 1 / Chagas C205 series
Evolva (Switzerland) – Projects: Discovery
Genzyme (USA) – Projects: Material transfer for research and development on HAT, Chagas disease, and leishmaniasis.
iThemba Labs (South Africa) – Projects: Lead optimization
Polytherics (UK) – Projects: Formulation of amphotericin B, in collaboration with Imperial College.
SCYNEXIS Inc. (USA) – Projects: Lead optimization / SCYX-2035811 / SCYX-1330682 SCYX-1608210 / Acoziborole / DNDi-5421 DNDi-5610 / DNDi-6148
Sequella, Inc. (USA) – Projects: Screening
Vertex (USA) – Projects: Screening
Universities
Addis Ababa University (Ethiopia) – Projects: VL-0208 / New treatments for HIV/VL / SSG&PM
Banaras Hindu University, Institute of Medical Sciences (India) – Projects: New treatments for PKDL
Baylor College of Medicine Children’s Foundation (Uganda) – Projects: LPV/r pellets with dual NRTI
Brasilia University (Brazil) – Projects: New VL treatments Latin America
Centres d’Investigation Clinique des Centres Hospitaliers Universitaires de Clermont-Ferrand (France) – Projects: Fexinidazole-Miltefosine combination
Federal University of Sergpipe (Brazil) – Projects: New VL treatments Latin America
Fundacao de Apoio Universidade Federale de Sao Paolo (FapUnifesp) (Brazil) – Projects: Lead optimization / Leish H2L / Chagas H2L / Chagas C205 series
Gondar University Hospital (Ethiopia) – Projects: VL-0208 / Miltefosine-Paromomycin combination for Africa / New treatments for HIV/VL / SSG&PM
Imperial College (UK) – Projects: Formulation of amphotericin B with Polytherics.
London School of Hygiene and Tropical Medicine (UK) – Projects: Screening / Lead optimization/ Aminopyrazoles / VL-0208 / VL-2098 / DNDi-5421 DNDi-5610 / CGH VL series 1 / Leish H2L / DNDi-6148 / DNDi-0690 / Fexinidazole-Miltefosine combination / New treatments for HIV/VL / SSG&PM / New VL treatments Asia / Nitroimidazole / Oxachagas / Chagas H2L / Biomarkers / Chagas C205 series
London School of Pharmacy (UK) – Projects: Formulation of amphotericin B, in collaboration with Imperial College.
Makarere University (Uganda) – Projects: Fexinidazole-Miltefosine combination / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa
McGill University (Canada) – Projects: Biomarkers / Flubendazole Macrofilaricide
Michigan State University (USA) – Projects: Flubendazole Macrofilaricide
Monash University, Centre for Drug Candidate Optimization (Australia) – Projects: Lead optimization / Fenarimol / Chagas H2L / Leish H2L / Chagas C205 series
Murdoch University, School of Veterinary and Biomedical Science (Australia) – Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization / Chagas C205 series
Montes Claros State University (Brazil) – Projects: New VL treatments Latin America
Nagasaki University (Japan) – Projects: CpG-D35
Ohio State University (USA) – Projects: CpG-D35
Pace University (USA) – Projects: SCYX-2035811 / SCYX-1330682 SCYX-1608210
Piaui Federal University (Brazil) – Projects: New VL treatments Latin America
Radboud University Medical Center (The Netherlands) – Projects: Fosravuconazole
Stellenbosch University (South Africa) – Projects: Superbooster therapy paediatric HIV/TB
Universidad Autónoma Juan Misael Saracho (Bolivia) – Projects: Biomarkers / Azoles E1224 / New benz regimens +/- fosravuconazole regimens / Fexinidazole (Chagas)
Universidade Estadual de Campinas UNICAMP (Brazil) – Project: Lead Optimization / Leish H2L / Chagas H2L / Chagas C205 series
University Hospital of Bonn, Institute of Medical Microbiology, Immunology and Parasitology (Germany) – Projects: Screening / Macro Filaricide 3
Universidad Mayor de San Simon (Bolivia) – Projects: Biomarkers / Azoles E1224 / New benz regimens +/- fosravuconazole regimens / Fexinidazole (Chagas)
Universidad Peruana Cayetano Heredia (Peru) – Projects: New CL combination therapies
Universidad San Martin (Argentina) – Projects: Biomarkers
Universidade Estadual do Rio de Janeiro (Brazil) – Projects: New VL treatments Latin America
University de Antioquia, Programa de Estudio y Control de Enfermedades Tropiales (Colombia) – Projects: Anfoleish / New CL combination therapies
University of Antwerp, Laboratory of Microbiology, Parasitology and Hygiene (Belgium) – Projects: Screening / Lead optimization / Leish H2L / Chagas H2L / SCYX-1330682 SCYX-1608210 / DNDi-5421 DNDi-5610 / Aminopyrazoles / DNDi-6148 / DNDi-0690 / VL-0208 / CGH VL series 1 / Nitroimidazole / Oxachagas / Chagas C205 series
University of Auckland (New Zealand) – Projects: Lead optimization / SCYX-2035811 / Nitroimidazole / DNDi-0690
University of Buea (Cameroon) – Projects: Flubendazole Macrofilaricide
University of Cape Town, Division of Clinical Pharmacology Department of Medicine (South Africa) – Projects: Screening / Superbooster therapy paediatric HIV/TB
University of Dundee, Drug Discovery Unit (UK) – Projects: Screening / Leish H2L / Chagas H2L / Chagas C205 series
University of Nairobi (Kenya) – Projects: LPV/r pellets with dual NRTI
University of Osaka (Japan) – Projects: CpG-D35
University of Witswatersrand, Perinatal HIV Research Unit (South Africa) – Projects: Superbooster therapy Paediatric HIV/TB
University of Texas at El Paso (USA) – Project: Biomarkers
Uppsala University (Sweden) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL / New treatments for PKDL / Miltefosine-Paromomycin combination for Africa
Utrecht University (The Netherlands) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infection / Miltefosine-Paromomycin combination for Africa
Various academic partners (South Africa and Kenya) – Projects: ‘4-in-1’ LPV/r/ABC/3TC
University of California (UCSF), San Francisco (USA) – Projects: K777 / Superbooster therapy Paediatric HIV/TB
University of North Carolina, Office of Technology Development (USA). Since 2007, DNDi partner through information sharing and discovery for NTDs.
Universidade Ouro Preto (Brazil) – Projects: Fenarimol / Nitroimidazole / Lead Optimization
University of Oxford, Worldwide Antimalarial Drug Resistance Network (UK) – Projects: ASAQ (Malaria) / ASMQ (Malaria)
University Sains (Malaysia) – Projects: ASAQ (Malaria) / ASMQ (Malaria)
University “Spin-off”
Epichem (Australia) – Projects: Screening / Leish H2L / Chagas H2L / Lead optimization / Fenarimol / Chagas C205 series
Eskitis Institute for Cell and Molecular Therapies, Griffith University (Australia) – Projects: Screening / Lead optimization/ Chagas H2L / Leish H2L / Chagas C205 series
Research Institutes
Broad Institute, MIT and Harvard (USA) – Projects: Discovery activity for Chagas disease
Dr Mario Fatala Chaben National Institute of Parasitology (Argentina) – Projects: Biomarkers
Fundacion Para el Estudio de las Infecciones Parasitarias y enfermedad de Chagas (FIPEC) (Argentina) Projects: Clinical studies for Chagas disease.
Georges Institute for International Health (Australia) – Projects: ASAQ
Ifakara Health Institute (Tanzania) – Projects: ASMQ
IMEA Consulting France: Institut de Médecine et d’Epidémiologie Appliquée, Département de Santé Tropicale (France) – Projects: ASAQ
Institut de Recherche pour le Développement (IRD) (France) – Projects: Acoziborole / Fexinidazole (HAT)
Institut de Recherche pour le Développement (IRD) (Sénégal) – Projects: ASAQ
Institut National de Recherche Biomédicale (DRC) – Projects: Acoziborole / Fexinidazole (HAT)
Institute of Tropical Medicine Antwerp (Belgium) – Projects: Acoziborole/ Fexinidazole (HAT) / New treatments for HIV/VL / VL-0208 / New VL treatments Asia
Instituto Nacional de Epidemiología Dr Fatala Cháben (Argentina) – Projects: New benz regimens +/- fosravuconazole / Paediatric dosage form of benznidazole
Institute of Endemic Disease (IEND), Khartoum University (Sudan), Leishmaniasis East Africa Platform (LEAP) – Projects: VL-0208 / SSG&PM / Fexinidazole-Miltefosine combination / New treatments for PKDL / Fosravuconazole / Miltefosine-Paromomycin combination for Africa
Institut Pasteur (France) – Projects: Screening
Institut Pasteur Korea (South Korea) – Projects: Screening / Leish H2L / Chagas H2L / Fenarimol / Chagas C205 series
Kenya Medical Research Institute (Kenya) – Projects: Fexinidazole-Miltefosine combination / Miltefosine-Paromomycin combination for Africa / LPV/r pellets with dual NRTI / SSG&PM / ASAQ / ASMQ
Kononklijk Instituut voor de Tropen (The Netherlands) – Projects: Fexinidazole-Miltefosine combination
Medical Research Council (UK) – Projects: ‘4-in-1’ LPV/r/ABC/3TC
National Institutes of Health (USA) – Projects: Screening / CpG-D35
Necker Institute (France) – Projects: ‘4-in-1’ LPV/r/ABC/3TC
Northwick Park Institute for Medical Research (UK) – Projects: Screening / Macro Filaricide 3
Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) (India) – Projects: New treatments for PKDL / New VL treatments Asia
Shandukani Research Centre Wits Reproductive Health and HIV Institute (South Africa) – Projects: Superbooster therapy paediatric HIV/TB
The Netherlands Cancer Institute (The Netherlands) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL / VL-0208 / New treatments for PKDL / Miltefosine-Paromomycin combination for Africa
The Swiss Tropical and Public Health Institute (Switzerland) – Projects: Screening / Leish H2L / Chagas H2L / Acoziborole / Fexinidazole (HAT) / NECT / SSG&PM / LPV/r pellets with dual NRTI
University of Georgia Research Foundation (USA) – Projects: Biomarkers
University of Georgia, The Center for Tropical and Emerging Global Diseases (CTEGD) (USA) – Projects: Azoles E1224
Walter Reed Army Institute (USA) – Projects: Screening
National Research Centres
Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) (Argentina) – Projects: Paediatric dosage form of benznidazole
B.P Koirala Institute of Health Sciences (Nepal) – Projects: Clinical trials for visceral leishmaniasis.
Brazilian Biosciences National Laboratory (LNBio), Centro Nacional de Pesquisa em Energia e Materiais (CNPEM) (Brazil) – Projects: Screening / Lead optimization / Chagas H2L / Chagas C205 series
Centre National de Recherche et de Formation sur le Paludisme (CNRFP) (Burkina Faso) – Projects: ASMQ
Central Drug Research Institute (CDRI) (India) – Projects: VL-2098 / DNDi-0690
Council of Scientific and Industrial Research (CSIR) (India) – Projects: Various partnerships for leishmaniasis and HAT through screening and discovery activities of anti-leishmaniasis compounds.
Erasmus Medical Centre (The Netherlands) – Projects: Fosravuconazole
Fiocruz, Fundaçao Oswaldo Cruz (Brazil) – Projects: Azoles E1224
Indian Council of Medical Research (ICMR) (India) – Projects: New VL treatments Asia / ASAQ / ASMQ
International Centre for Diarrhoeal Disease Research (Bangladesh) – Projects: New treatments for PKDL / New VL treatments Asia
IS Global, Centre de Recerca en Salut Internacional de Barcelona (CRESIB) (Spain) – Projects: Screening / Biomarkers / New benz regimens +/- fosravuconazole / Fexinidazole (Chagas) / Azoles E1224
Joint Clinical Research Centre (Uganda) – Projects: LPV/r pellets with dual NRTI
Kala Azar Medical Research Centre (India) – Projects: New treatments for PKDL / New VL treatments Asia
Medical Research Council (UK) – Projects: ‘4-in-1’ LPV/r/ABC/3TC
Mycetoma Research Centre, Soba University Hospital (Sudan) – Projects: Fosravuconazole
National Institute for Medical Research (NIMR) (Tanzania) – Projects: ASMQ
National Vector Borne Disease Control Programme (India) – Projects: New VL treatments Asia
Northwick Park Institute for Medical Research (UK) – Projects: Screening
Novartis Centre de la Recherche Santé Animale (Switzerland) – Projects: Screening
Rene Rachou Research Center, Fiocruz MG (Brazil) – Projects: New VL treatments Asia / New VL treatments Latin America
Seattle Biomedical Research Institute (USA) – Projects: Discovery for NTDs.
Texas Biomedical Research (USA) – Projects: Biomarkers
NGOs/IOs
AEDES, consulting firm for Social and Public health sector (Belgium) – Projects: ASAQ
Clinton Access Health Initiative (USA) – Projects: LPV/r pellets with dual NRTI
Collective of Applied Studies and Social Development (CEADES) (Bolivia) – Projects: Azoles E1224 / New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)
Communauté Baptiste du Congo (CBCO) (Democratic Republic of Congo) – Projects: Fexinidazole (HAT)
Epicentre (France) – Projects: NECT / ASAQ / ASMQ
Epicentre Research Center (Uganda) – Projects: LPV/r pellets with dual NRTI
Fundación Mundo Sano and ELEA (Argentina) – Projects: New benz regimens +/- fosravuconazole / Paediatric dosage form of benznidazole
IDA Foundation (The Netherlands) – Projects: VL-0208 / SSG&PM
i+solutions (The Netherlands) – Projects: VL-0208 / SSG&PM / New treatments for PKDL
Médecins Sans Frontières – Projects: ASAQ / NECT / Fexinidazole (HAT) / Fexinidazole-Miltefosine combination / New treatments for HIV/VL / VL-0208 / New VL treatments Asia / SSG&PM / Generic Ambisome / Biomarkers / Azoles E1224 / Fexinidazole (Chagas) / ‘4-in-1’ LPV/r/ABC/3TC
Microbial Chemistry Research Foundation (Japan) – Projects: Screening
Offre Technique d’Etude et de Coopération Internationale (OTECI) (France) – Projects: ASMQ
Royal Society of Chemistry (UK): MoU to promote open source discovery.
UNITAID (Switzerland) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI
WHO-TDR: (Switzerland) – Projects: ASAQ / ASMQ / Screening / New VL treatments Asia
PDPs/PPPs
FIND, Foundation for Innovative New Diagnostics (Switzerland) – Projects: Collaboration and material transfer agreement to develop an ELISA-based diagnostic test for leishmaniasis. MoU for collaboration in the field of neglected tropical diseases.
Medicines for Malaria Venture (MMV) (Switzerland) – Projects: Screening / ASAQ / ASMQ
Novartis Institute for Tropical Diseases (Singapore) – Projects: Lead optimization
Institute for One World Health (OWH) (USA) – Projects: VL-0208 / New VL treatments Asia / SSG&PM
TB Alliance (USA) – Projects: Nitroimidazole / SCYX-2035811 / VL-2098 / Screening / Lead optimization/ DNDi-0690
TI Pharma (The Netherlands) – Projects: DNDi partner for discovery activities.
Hospitals
Amudat General Hospital (Uganda) – Projects: Fexinidazole-Miltefosine combination / SSG&PM / Miltefosine-Paromomycin combination for Africa
Arba Minch Hospital (Ethiopia) – Projects: SSG&PM
CHUV, Centre Hospitalier Universitaire Vaudois (Switzerland) – Projects: ASMQ
Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital (South Africa) – Projects: Superbooster therapy paediatric HIV/TB
Gertrude’s Children’s Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI
Hospital de Niños de Jujuy (Argentina) – Projects: Paediatric dosage form of benznidazole
Hospital de Niños Dr. Ricardo Gutiérrez (Argentina) – Projects: Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole
Hospital General Universitari de Valencia (Spain) – Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)
Hospital Independencia, Centro de Chagas y Patologia Regional (Argentina) – Projects: Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole
Hospital Público Materno Infantil (Argentina) – Projects: Paediatric dosage form of benznidazole
Hospital Sao José de Doencas Infecciosas (Brazil) – Projects: New VL treatments Latin America
Kacheliba District Hospital (Kenya) – Projects: Fexinidazole-Miltefosine combination
KATH, Komfo Anokye Teaching Hospital (Ghana) – Projects: ASAQ
Mbagathi District Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI
Moi Teaching and Referral Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI
National Museum of Natural History Paris (MNHN) (France) – Projects: Screening
Paediatric Hospital Joao Paulo II – FHEMIG (Brazil) – Projects: New VL treatments Latin America
Shaheed Suhrawardy Medical College and Hospital (Bangladesh) – Projects: New VL treatments Asia
St. Lumumba Health Centre (Kenya) – Projects: LPV/r pellets with dual NRTI
Tygerberg Children’s Hospital (South Africa) – Projects: Superbooster therapy paediatric HIV/TB
University Hospitals of Geneva (Switzerland) – Projects: Biomarkers / Macro Filaricide 3
Ministries of Health/Governmental Organizations
Gedarif MoH (Sudan). Leishmaniasis East Africa Platform (LEAP) Projects: Various partnerships for clinical trials in the field of leishmaniasis / VL-0208 / SSG&PM
Bihar State Health Society (India) Projects: New VL treatments Asia
Centre for Disease Control and Prevention CDC/President’s Emergency Plan for AIDS Relief (USA) Projects: ‘4-in-1’ LPV/r/ABC/3TC
Centro Nacional de Diagnostico e Investigacion de Endemo-epidemias (CeNDIE), Ministry of Health, (Argentina) Projects: Paediatric dosage form of benznidazole
Clinical Research Malaysia, Ministry of Health (Malaysia) Projects: Ravidasvir/Sofosbuvir
Department of Health and Department of Science and Technology (South Africa) Projects: Superbooster therapy paediatric HIV/TB
Department of Health South Africa (South Africa) Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI
Food & Drug Administration (FDA) (US) Projects: CpG-D35
Ministry of Health, Leishmaniasis Control Programme (Brazil) Projects: New VL treatments (Latin America)
Ministry of Health, National Malaria Control Programme (Burundi) Projects: ASAQ
Ministry of Health (Cambodia) Projects: ASMQ
Ministry of Health (DRC) Projects: Various partnerships (financial and clinical trial agreement) in the field of HAT / NECT
Ministry of Health (Ethiopia) Projects: SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa
Ministry of Health (Ghana) Projects: ASAQ
Ministry of Health (Kenya) Projects: LPV/r pellets with dual NRTI / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa
Ministry of Health (Sierra Leone) Projects: ASAQ
Ministry of Health (Sudan) Projects: New treatments for PKDL / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa
Ministry of Health (Uganda) Projects: SSG&PM / VL-0208
Ministry of Health and Family Welfare (Bangladesh) Projects: New VL treatments Asia
Ministry of Health, Province of Jujuy (Argentina) Projects: Paediatric dosage form of benznidazole
National Trypanosomiasis Control Programme (DRC) Projects: NECT / Acoziborole
Contract Research Organizations (CROs)
Accelera (Italy) – Projects: VL-2098 / DNDi-0690 / DNDi-6148
Advinus Therapeutics Ltd. (India) – Projects: Acoziborole / VL-2098 / DNDi-0690
Aptuit (Italy) – Projects: DNDi-0690 / Fexinidazole-Miltefosine combination / VL-2098 / Fexinidazole (HAT)
BaseCon (Denmark) Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL
Bertin Pharma (France) Projects: ASAQ (Malaria) / VL-2098 / Acoziborole / Fexinidazole (HAT)
Cardiabase (France) Projects: Fexinidazole-Miltefosine combination / Acoziborole / Fexinidazole (HAT)
Calvert Labs (USA) Projects: Pre-clinical phase for topical formulation against cutaneous leishmaniasis.
Cardinal System (France) Projects: Azoles E1224
Catalent (USA) Projects: Screening, discovery, clinical activities as well as registration and regulatory issues in the field of malaria.
Centipharm (France) Projects: CMC/manufacture of fexinidazole for HAT.
Central Diagnostics (India) Projects: Partner in the field of visceral leishmaniasis.
Clinwin Research Services (Kenya) Projects: ASMQ (Malaria)
CoreLab Partners (USA) Projects: Clinical activity for Chagas disease.
Covance (UK) Projects: VL-2098
Creapharm (France) Projects: Fexinidazole (Chagas)
Drugabilis (France) Projects: Screening & Lead Optimization / Fexinidazole (HAT) / Oxaborole SCYX-7158 (HAT) / Flubendazole (Filarial diseases) / VL-2098
Endolytics (USA) Projects: VL-2098
Eurofins Optimed (France) Projects: Oxaborole SCYX-7158 (HAT) / Two “4-in-1” LPV/r based FDC granules (Paediatric HIV)
Frontage (USA) Projects: Azoles E1224 & Biomarker (Chagas)
GVK Biosciences (India) Projects: Clinical phase for malaria and VL.
Harlan Laboratories (Switzerland) Projects: Pre-clinical research agreement for Chagas disease.
Huntingdon Life Sciences Limited (UK) Projects: VL-2098
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres”, National Council of Scientific and Technological Research (INGEBI-CONICET) (Argentina) Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas) / Biomarkers / Azoles E1224 / Paediatric dosage form of benznidazole
JSS Medical Research (Canada) Projects: Anfoleish (CL) / Fexinidazole (Chagas)
LAT Research (Argentina) Projects: Azoles E1224 & Biomarker (Chagas)
Nucleo de desenvolvimento farmacêutico e cosméticos (NUDFAC) (Brazil) Projects: Azoles E1224 & Biomarker (Chagas) / Paediatric Benznidazole (Chagas)
Patheon (UK) Projects: Formulation development and manufacturing for HAT.
Penn Pharmaceuticals Services (UK) Projects: Oxaborole SCYX-7158 (HAT)
PhinC (France) – Projects: Fexinidazole-Miltefosine combination
RCTs (France) Projects: NECT (HAT) / Fexinidazole (HAT)
Roowin (France) Projects: CMC activities for HAT.
Sandexis (UK) Projects: Lead optimization/ Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / CGH VL series 1 / Chagas H2L / DNDi-6148
Sigma-Aldrich (UK) Projects: VL-2098
SGS (France). Projects: Clinical study of fexinidazole for HAT, subsequently performing bioanalyses.
SGS (Belgium) Projects: Fexinidazole-Miltefosine combination
Theradis Pharma (France) Projects: Fexinidazole (HAT)
WuXi AppTech (China) Projects: Screening/ Lead optimization/ Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / CGH VL series 1 / Chagas H2L / DNDi-6148 / DNDi-0690 / Two ‘4-in-1’ LPV/r based FDC granules
Platforms and Networks
HAT Platform Projects: NECT
Leishmaniasis East Africa Platform Projects: Fexinidazole-Miltefosine combination / New treatments for PKDL / New treatments for HIV/VL coinfection / SSG&PM
National Control Programmes of the DRC and CAR Projects: Fexinidazole
NHEPACHA Network Projects: Biomarkers
Platform of Integral Care for Patients with Chagas Disease (Bolivia) Projects: New benznidazole regimens/ Fexinidazole
Please contact us at partnership@dndi.org to propose collaborative projects.